학술논문
Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada
Document Type
Academic Journal
Author
Costiniuk, Cecilia T.; Singer, Joel; Lee, Terry; Galipeau, Yannick; McCluskie, Pauline S.; Arnold, Corey; Langlois, Marc-André; Needham, Judy; Jenabian, Mohammad-Ali; Burchell, Ann N.; Samji, Hasina; Chambers, Catharine; Walmsley, Sharon; Ostrowski, Mario; Kovacs, Colin; Tan, Darrell H.S.; Harris, Marianne; Hull, Mark; Brumme, Zabrina L.; Lapointe, Hope R.; Brockman, Mark A.; Margolese, Shari; Mandarino, Enrico; Samarani, Suzanne; Vulesevic, Branka; Lebouché, Bertrand; Angel, Jonathan B.; Routy, Jean-Pierre; Cooper, Curtis L.; Anis, Aslam H.
Source
AIDS. Oct 01, 2023 37(12):F25-F35
Subject
Language
English
ISSN
0269-9370
Abstract
OBJECTIVES:: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Here, we compare coronavirus disease 2019 (COVID-19) vaccine-induced antibody neutralization capacity in PWH vs. HIV-negative individuals following two vaccine doses. DESIGN:: In Canadian prospective observational cohorts, including a multicentre study of PWH receiving at least two COVID-19 vaccinations (mRNA or ChAdOx1-S), and a parallel study of HIV-negative controls (Stop the Spread Ottawa Cohort), we measured vaccine-induced neutralization capacity 3 months post dose 2 (±1 month). METHODS:: COVID-19 neutralization efficiency was measured by calculating the half maximal inhibitory dilution (ID50) using a high-throughput protein-based neutralization assay for Ancestral (Wuhan), Delta and Omicron (BA.1) spike variants. Univariable and multivariable quantile regression were used to compare COVID-19-specific antibody neutralization capacity by HIV status. RESULTS:: Neutralization assays were performed on 256 PWH and 256 controls based on specimen availability at the timepoint of interest, having received two vaccines and known date of vaccination. There was a significant interaction between HIV status and previous COVID-19 infection status in median ID50. There were no differences in median ID50 for HIV+ vs. HIV-negative persons without past COVID-19 infection. For participants with past COVID-19 infection, median ICD50 was significantly higher in controls than in PWH for ancestral SARS-CoV-2 and Omicron variants, with a trend for the Delta variant in the same direction. CONCLUSION:: Vaccine-induced SARS-CoV-2 neutralization capacity was similar between PWH vs. HIV-negative persons without past COVID-19 infection, demonstrating favourable humoral-mediated immunogenicity. Both HIV+ and HIV-negative persons demonstrated hybrid immunity. TRIAL REGISTRATION:: clinicaltrials.gov NCT04894448.